Breaking News Instant updates and real-time market news.

CNCE

Concert Pharmaceuticals

$27.68

-0.35 (-1.25%)

, INCY

Incyte

$93.06

-3.56 (-3.68%)

07:03
01/12/18
01/12
07:03
01/12/18
07:03

Concert Pharmaceuticals says PTAB did not grant PGR petition

Concert Pharmaceuticals (CNCE) announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office has decided not to grant the company's Post Grant Review petition challenging the validity of U.S. Patent No. 9,662,335 assigned to Incyte Pharmaceuticals (INCY). "We are disappointed that the PTAB has denied our petition on the '335 patent. This decision does not prohibit us from challenging the validity of the patent at a later time in federal court, and we will continue with our plans to develop CTP-543 for alopecia areata. We don't expect any disruption to our clinical timelines," said Roger Tung, president and CEO. "We remain committed to developing the first FDA-approved treatment for alopecia areata; however, we are reassessing whether to expand CTP-543 into additional indications." In July 2017, Concert filed a PGR petition challenging the validity of Incyte's '335 patent covering deuterated ruxolitinib analogs.

CNCE

Concert Pharmaceuticals

$27.68

-0.35 (-1.25%)

INCY

Incyte

$93.06

-3.56 (-3.68%)

  • 18

    Jan

CNCE Concert Pharmaceuticals
$27.68

-0.35 (-1.25%)

12/19/17
UBSW
12/19/17
NO CHANGE
Target $34
UBSW
Buy
Concert Pharmaceuticals price target raised to $34 from $22 at UBS
UBS analyst Jeffrey Hung raised his price target on Concert Pharmaceuticals to $34 from $22 to reflect higher than expected demand for novel alopecia treatments. He continues to see a substantial opportunity for its alopecia treatment and increased his launch assumptions. The analyst also pointed to the company's clinical candidates that demonstrate the strategic value of the platform and pipeline optionality. Hung reiterated his Buy rating on Concert Pharmaceuticals shares.
07/24/17
HCWC
07/24/17
INITIATION
Target $20
HCWC
Buy
Concert Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Concert Pharmaceuticals with a Buy rating, stating that recent lifting of a clinical hold on CTP-543 removed an overhang and cleared the path for Phase 2a readout next year. The analyst, who is bullish on the long-term potential of CTP-543 in alopecia areata, set a $20 price target on Concert shares.
05/17/17
STFL
05/17/17
NO CHANGE
Target $31
STFL
Buy
Resolution of Concert clinical hold should take quarter 'at most,' says Stifel
After Concert Pharmaceuticals announced that that FDA has placed the company's CTP-543 Phase 2 trial for alopecia areata on clinical hold, Stifel analyst Adam Walsh noted that no safety concerns were highlighted and that Concert already has the data of interest in-house, leading him to believe that the resolution of the hold will take a quarter "at most." The analyst, who still expects Concert to initiate and enroll the trial in 2017 and continues to project U.S. approval and launch in FY20, recommends buying on weakness and keeps a Buy rating and $31 price target on Concert shares.
04/05/17
STFL
04/05/17
NO CHANGE
Target $31
STFL
Buy
Concert weakness a buying opportunity, says Stifel
Stifel analyst Adam Walsh said he believes the clinical tablet appearance issue that Concert Pharmaceuticals blamed for the delay in the start of its alopecia areata trial should be relatively easy to fix and only result in a minor delay. He continues to project U.S. approval and launch in FY20 and recommends shares be bought on related weakness. Walsh keeps a Buy rating and $31 price target on Concert shares.
INCY Incyte
$93.06

-3.56 (-3.68%)

01/08/18
STFL
01/08/18
NO CHANGE
STFL
Buy
NewLink Genetics timelines mostly in-line with prior guidance, says Stifel
Stifel analyst Stephen Willey noted that NewLink Genetics (NLNK) now expects to complete the majority of enrollment in the Indigo301 melanoma trial by year-end, versus its previous expectation to complete enrollment in 2018, which he said is likely due to additional time required for dose optimization of the novel indoximod salt formulation. The remainder of the 2018 calendar the company laid out is full of mostly expected catalysts and in-line with prior guidance, said Willey, who still expects NewLink to remain levered to Incyte's (INCY) date from the Phase 3 ECHO-301 trial. Willey keeps a Buy rating on NewLink shares.
01/08/18
DBAB
01/08/18
NO CHANGE
Target $110
DBAB
Buy
Celgene deal 'incremental negative' for Incyte, says Deutsche Bank
Deutsche Bank analyst Navin Jacob calls Celgene's (CELG) acquisition of Impact Biomedicines "one step" in the right direction. The analyst estimates Impact's Jak2 inhibitor fedratinib can achieve 20% of peak Jakafi sales in myelofibrosis and polycythemia vera, which translates to $1B. The asset fits Celgene's business and the $2.4B that the company is paying over the next two years "doesn't appear egregious for a commercial ready asset," Jacob tells investors in a research note. The analyst also views Celgene's acquisition as an "incremental negative" for Incyte (INCY). Given direct overlap, any future potential acquisition of Incyte by Celgene has been removed, Jacob contends. He keeps a Hold rating on Celgene with a $110 price target.
01/02/18
OPCO
01/02/18
NO CHANGE
Target $120
OPCO
Perform
Incyte price target lowered to $120 from $135 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte to $120 from $135, citing share underperformed following the presentation of updated ECHO-202 data for epacadostat+Keytruda in advanced melanoma at ESMO. The analyst believes the Incyte share price decline was driven by loss of M&A premium as investors became disappointed by limited Biotech deal activity, concern about potential share price impact of ECHO-301 results in 1H18, and nervousness about the data at ESMO. Olson reiterates an Perform rating on the shares.
01/02/18
RBCM
01/02/18
UPGRADE
RBCM
Outperform
Incyte upgraded to Outperform at RBC Capital on improved risk-reward
As reported earlier, RBC Capital analyst Brian Abrahams upgraded Incyte to Outperform from Sector Perform. Abrahams says the 31% decline in the stock price from the September high makes for more substantially improved risk-reward profile as expectations for the phase 3 epa melanoma readout have come down. The analyst says he remains bullish on the long-term growth prospects for Jakafi, modeling its undiscounted, taxed cash flows through end-2026 patent expiry of about $14B.

TODAY'S FREE FLY STORIES

SNE

Sony

$48.38

-0.22 (-0.45%)

20:47
05/21/18
05/21
20:47
05/21/18
20:47
Hot Stocks
Sony targets operating cash flow of Y2T as part of its mid-range plan »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

BOFI

BofI Holding

$41.97

0.29 (0.70%)

20:40
05/21/18
05/21
20:40
05/21/18
20:40
Downgrade
BofI Holding rating change at Compass Point »

BofI Holding downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 24

    Sep

SNE

Sony

$48.38

-0.22 (-0.45%)

20:32
05/21/18
05/21
20:32
05/21/18
20:32
Hot Stocks
Sony confirms to acquire 60% equity interest in DH Publishing which manages EMI »

Mubadala Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

SNE

Sony

$48.38

-0.22 (-0.45%)

20:25
05/21/18
05/21
20:25
05/21/18
20:25
Conference/Events
Sony to hold IR Day 2018 »

Sony IR Day 2018 to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

TJX

TJX

$84.66

-0.15 (-0.18%)

, AZO

AutoZone

$665.68

13.03 (2.00%)

20:25
05/21/18
05/21
20:25
05/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TJX

TJX

$84.66

-0.15 (-0.18%)

AZO

AutoZone

$665.68

13.03 (2.00%)

KSS

Kohl's

$65.47

1.79 (2.81%)

AAP

Advance Auto Parts

$119.18

0.93 (0.79%)

EV

Eaton Vance

$58.05

0.52 (0.90%)

TOL

Toll Brothers

$43.60

0.43 (1.00%)

IGT

International Game

$29.75

-0.655 (-2.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 24

    May

  • 24

    May

ADBE

Adobe

$238.00

-0.04 (-0.02%)

19:54
05/21/18
05/21
19:54
05/21/18
19:54
Recommendations
Adobe analyst commentary at JPMorgan »

Adobe adds the missing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

SNE

Sony

$48.38

-0.22 (-0.45%)

19:36
05/21/18
05/21
19:36
05/21/18
19:36
Periodicals
Breaking Periodicals news story on Sony »

Sony to buy out remaining…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

K

Kellogg

$60.77

0.58 (0.96%)

19:28
05/21/18
05/21
19:28
05/21/18
19:28
Conference/Events
Kellogg management to meet with JPMorgan »

Meetings to be held New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 25

    May

ST

Sensata

$52.58

(0.00%)

19:24
05/21/18
05/21
19:24
05/21/18
19:24
Earnings
Sensata backs FY18 EPS view $3.57-$3.73 following valves business sale »

Consensus $3.66. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

ST

Sensata

$52.58

(0.00%)

19:22
05/21/18
05/21
19:22
05/21/18
19:22
Hot Stocks
Sensata enters $173M deal to sell its valves business to Pacific Industrial Co »

Sensata Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

ELLI

Ellie Mae

$104.16

0.35 (0.34%)

19:20
05/21/18
05/21
19:20
05/21/18
19:20
Conference/Events
Ellie Mae management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 24

    May

  • 12

    Jun

FB

Facebook

$184.48

1.79 (0.98%)

19:19
05/21/18
05/21
19:19
05/21/18
19:19
Periodicals
U.K. lawmakers seek answers from Facebook CEO on data misuse, Reuters says »

U.K. lawmakers want…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

BA

Boeing

$363.95

12.71 (3.62%)

19:18
05/21/18
05/21
19:18
05/21/18
19:18
Periodicals
Boeing Charleston workers to vote on union representation on May 31, WSJ says »

The U.S. National Labor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

ESLOY

Essilor

$0.00

(0.00%)

19:17
05/21/18
05/21
19:17
05/21/18
19:17
Conference/Events
Essilor management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

WIX

Wix.com

$85.45

-3.25 (-3.66%)

, SHOP

Shopify

$144.58

-2.45 (-1.67%)

19:06
05/21/18
05/21
19:06
05/21/18
19:06
Recommendations
Wix.com, Shopify, Adobe analyst commentary at JPMorgan »

After Magento deal, Adobe…

WIX

Wix.com

$85.45

-3.25 (-3.66%)

SHOP

Shopify

$144.58

-2.45 (-1.67%)

ADBE

Adobe

$238.00

-0.04 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 12

    Jun

MU

Micron

$55.48

2.11 (3.95%)

19:05
05/21/18
05/21
19:05
05/21/18
19:05
Conference/Events
Micron management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 30

    May

GSM

Ferroglobe

$11.35

0.36 (3.28%)

, CRMT

America's Car-Mart

$54.60

-0.05 (-0.09%)

19:00
05/21/18
05/21
19:00
05/21/18
19:00
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

GSM

Ferroglobe

$11.35

0.36 (3.28%)

CRMT

America's Car-Mart

$54.60

-0.05 (-0.09%)

MU

Micron

$55.48

2.11 (3.95%)

MUFG

Mitsubishi UFJ

$6.45

-0.01 (-0.15%)

AKAM

Akamai

$76.46

1.13 (1.50%)

ADBE

Adobe

$238.00

-0.04 (-0.02%)

PSTG

Pure Storage

$23.60

-0.065 (-0.27%)

NDSN

Nordson

$139.50

4.45 (3.30%)

IGT

International Game

$29.75

-0.655 (-2.15%)

LBY

Libbey

$6.84

-0.27 (-3.80%)

ARDX

Ardelyx

$5.65

-0.15 (-2.59%)

SAIL

SailPoint

$22.43

-0.16 (-0.71%)

CADE

Cadence Bancorp

$29.07

0.01 (0.03%)

TWOU

2U

$95.50

-0.16 (-0.17%)

MYOK

MyoKardia

$48.30

-3.45 (-6.67%)

SHOP

Shopify

$144.58

-2.45 (-1.67%)

AIR

AAR Corp.

$47.70

0.74 (1.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 24

    May

  • 30

    May

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 26

    Jun

  • 10

    Jul

  • 10

    Sep

  • 24

    Sep

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 24

    May

AVA

Avista

$52.62

0.07 (0.13%)

18:55
05/21/18
05/21
18:55
05/21/18
18:55
Hot Stocks
CFIUS says no unresolved security concerns over Hydro One-Avista deal »

Hydro One Limited and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DEST

Destination Maternity

$2.68

-0.03 (-1.11%)

18:40
05/21/18
05/21
18:40
05/21/18
18:40
Hot Stocks
Investors say Destination Maternity needs 'fresh perspectives' »

Nathan G. Miller and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

ARWR

Arrowhead

$9.78

-0.21 (-2.10%)

18:35
05/21/18
05/21
18:35
05/21/18
18:35
Conference/Events
Arrowhead management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

JHX

James Hardie

$17.32

(0.00%)

18:31
05/21/18
05/21
18:31
05/21/18
18:31
Earnings
James Hardie reports FY18 net profit $146.1M vs. $276.5M last year »

Reports FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WST

West Pharmaceutical

$90.13

0.88 (0.99%)

18:27
05/21/18
05/21
18:27
05/21/18
18:27
Conference/Events
West Pharmaceutical management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

  • 19

    Jun

SSRM

SSR Mining

$10.30

0.02 (0.19%)

18:20
05/21/18
05/21
18:20
05/21/18
18:20
Conference/Events
SSR Mining management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

PDCE

PDC Energy

$65.33

1.57 (2.46%)

18:18
05/21/18
05/21
18:18
05/21/18
18:18
Hot Stocks
PDC Energy Amidon sells 8,045 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

GSM

Ferroglobe

$11.35

0.36 (3.28%)

18:15
05/21/18
05/21
18:15
05/21/18
18:15
Conference/Events
Ferroglobe management to meet with Jefferies »

Meeting to be held in w…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 22

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.